Company / Operating Income
Sunshine Biopharma Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$5.8M
FY2025
5-year range
-$27.0M / -$576.9K
FY2021-FY2025
Trend
-21.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$27M in FY2023 to -$576,874 in FY2021.
Based on SEC 10-K filings.
-$6M in FY2025.
Improved from -$27M to -$6M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 21.5% year-over-year.
- Peak operating income was recorded in FY2021.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.8M | -21.5% |
| FY2024 | -$4.8M | +82.3% |
| FY2023 | -$27.0M | -1006.5% |
| FY2022 | -$2.4M | -323.0% |
| FY2021 | -$576.9K | +10.1% |
| FY2020 | -$641.6K | +44.9% |
| FY2019 | -$1.2M | -35.8% |
| FY2018 | -$857.2K | +13.7% |
| FY2017 | -$993.1K | -27.3% |
| FY2016 | -$780.3K | +55.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026